LRMR
Larimar Therapeutics, Inc.3.7400
-0.1800-4.59%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
320.11MP/E (TTM)
-Basic EPS (TTM)
-1.96Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
Nomlabofusp data boosts FA hopes
Larimar Therapeutics updated its corporate presentation on October 14, 2025, highlighting positive open-label study data for nomlabofusp in Friedreich's ataxia. All participants achieved skin frataxin levels over 50% of healthy volunteers by six months, with median mFARS improvements of 2.25 after one year versus worsening in natural history controls. Nomlabofusp proved well-tolerated long-term, despite early anaphylaxis cases prompting a modified dosing regimen endorsed by the FDA. Cash stands at $175.7 million, funding into Q4 2026; BLA submission targets Q2 2026 for accelerated approval. Anaphylaxis risks persist early in treatment.
8-K
Positive nomlabofusp data boosts FA hopes
Larimar Therapeutics unveiled positive data from its ongoing open-label study of nomlabofusp in Friedreich's ataxia patients, showing sustained skin frataxin increases to over 50% of healthy volunteer levels in all 10 participants at six months, alongside directional improvements in four key clinical outcomes like mFARS after one year—contrasting with disease worsening in a natural history reference. While seven anaphylaxis cases prompted a modified starting dose regimen, which the FDA endorsed, long-term daily dosing proved generally well-tolerated. BLA submission for accelerated approval targets Q2 2026. Safety risks persist early in treatment.
10-Q
Q2 FY2025 results
Larimar Therapeutics posted a Q2 net loss of $26.2M, up 21% y/y from $21.6M, driven by R&D expenses climbing to $23.4M from $19.7M amid ramped-up nomlabofusp trials and manufacturing. Operating loss widened to $27.8M y/y, with diluted EPS slipping to $(0.41) on 64.0M shares, consistent with no anti-dilution effects. YTD net loss hit $55.5M, 53% higher y/y, as cash burn accelerated to $45.9M from operating activities, leaving $138.5M in cash and equivalents at quarter-end; a $65.1M stock offering in July bolsters runway into Q4 2026. Progress shines in the open label study, now dosing at 50mg with FDA nods for skin FXN as a surrogate endpoint toward a Q2 2026 BLA. Cash flows freely from maturities. Yet regulatory delays could stall the path.
BLRX
BioLineRx Ltd.
3.01-0.17
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
IMMX
Immix Biopharma, Inc.
5.94-0.27
KALA
KALA BIO, Inc.
0.56-0.05
LBRX
LB Pharmaceuticals Inc
19.82-0.04
LIMN
Liminatus Pharma, Inc.
0.78+0.02
LSTA
Lisata Therapeutics, Inc.
2.05+0.01
MRKR
Marker Therapeutics, Inc.
1.27-0.12
OMER
Omeros Corporation
8.77-0.43
RLMD
Relmada Therapeutics, Inc.
4.50+0.14